alexa

GET THE APP

Effects of Plasmalogen on Patients with Moderate-to-Severe Alzheimer's Disease and Blood Plasmalogen Changes: A Multi-Center, Open-Label Study | OMICS International| Abstract
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Alzheimers Dis Parkinsonism 2019, Vol 9(4): 474
  • DOI: 10.4172/2161-0460.1000474

Effects of Plasmalogen on Patients with Moderate-to-Severe Alzheimer's Disease and Blood Plasmalogen Changes: A Multi-Center, Open-Label Study

Takehiko Fujino1*, Tatsuo Yamada2, Shiro Mawatari1, Naotaka Shinfuku3, Yoshio Tsuboi4, Chikako Wakana3 and Suminori Kono5
1Institute of Rheological Functions of Food, 2241-1 Kubara, Hisayama-chou, Kasuya-gun, Fukuoka 811-2501, Japan
2Gotanda Rehabilitation Hospital, 8-8-20 Nishigotanda, Shinagawa-ku, Tokyo 141-0031, Japan
3BOOCS Clinic Fukuoka, 6-18 Tenya-machi, Hakata-ku, Fukuoka 812-0025, Japan
4Department of Neurology, School of Medicine, Fukuoka University, 7-45-1 Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan
5MedStat Corporation, 1-1 Naraya-machi, Hakata-ku, Fukuoka 810-0023, Japan
*Corresponding Author : Takehiko Fujino, Institute of Rheological Functions of Food, 2241-1 Kubara, Hisayama-chou, Kasuya-gun, Fukuoka, Japan, Tel: +81 92 273 2420, Email: [email protected]

Received Date: Jul 29, 2019 / Accepted Date: Aug 13, 2019 / Published Date: Aug 23, 2019

Abstract

Objective: Plasmalogens (Pls) are a special class of glycerophospholipids containing a vinyl ether bond at the sn-1 position. Recently, it has become clear that Pls are closely related to Alzheimer’s disease (AD). Pls levels have been found to be decreased in the brain and blood of patients with AD. We previously reported that Pls could improve cognitive function in AD animal models and in a randomized controlled trial of patients with mild cognitive impairment and mild AD. This study aimed to investigate the effect of Pls on patients with moderate-to-severe AD in an open-label study.
Methods: Eligible patients were Japanese patients aged 60-85 years who had <20 points of the Mini-Mental State Examination (MMSE) score. They received 1.0 mg or 0.5 mg of scallop-derived Pls per day for 12 weeks. The primary outcome was the MMSE score, and the secondary one was blood concentration of phosphatidylethanolamine Pls (PlsPE).
Results: A total of 157 patients were enrolled, and 142 participants completed the study. The patients showed a statistically significant improvement in the MMSE score after the treatment, and the increase did not differ by treatment dose. Erythrocyte and plasma PlsPE, which were prominently lower than those of normal subjects at baseline, increased significantly after the treatment in the whole patients. While the increase in erythrocyte PlsPE did not significantly differ in the 1.0 mg and 0.5 mg groups, plasma PlsPE increased more markedly in the 0.5 mg group
than in the 1.0 mg group (P=0.001). The change in erythrocyte PlsPE, but not the change in plasma PlsPE, showed a modest degree of correlation with the change in MMSE score (Pearson’s r=0.20, P=0.01).
Conclusion: These findings suggest that orally administered scallop-derived Pls improve cognitive function and that the measurement of blood Pls is valuable to assess the severity and treatment progress in patients with moderate-to-severe AD.

Keywords: Plasmalogen; Scallop; Alzheimer’s disease; Moderate-tosevere AD; Cognitive function; Biomarker of severity; Mini-mental state examination

Citation: Fujino T, Yamada T, Mawatari S, Shinfuku N, Tsuboi Y, et al. (2019) Effects of Plasmalogen on Patients with Moderate to Severe Alzheimer’s disease and Blood Plasmalogen Changes: A Multi-Center, Open-Label Study. J Alzheimers Dis Parkinsonism 9: 474. Doi: 10.4172/2161-0460.1000474

Copyright: © 2019 Fujino T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top